Test Price
2,800 AED✅ Home Collection Available
CCDC65 Gene Primary Ciliary Dyskinesia Type 27 Genetic Test in UAE | 2,800 AED | 2026 DHA Guidelines
تحليل جين CCDC65 للخلل الهدبي الأولي من النوع 27 في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary: This advanced Genetic Test achieves 99.9% diagnostic sensitivity for Primary Ciliary Dyskinesia Type 27, accredited under ISO 9001:2015. Included are hospital‑grade home collection, cold‑chain logistics, and telephonic post‑test clinical guidance.
ملخص تنفيذي: يوفر هذا التحليل الجيني المتطور حساسية تشخيصية 99.9٪ للخلل الهدبي الأولي من النوع 27 باستخدام تقنية التسلسل الجيني فائق الجودة، والمعتمدة وفق معيار ISO 9001:2015. تشمل الخدمة تجميعًا منزليًا بمستوى المستشفى، ولوجستيات سلسلة التبريد، وإرشادات طبية عبر الهاتف بعد الفحص.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731
Overview
This CCDC65 gene test uses Next‑Generation Sequencing (NGS) to identify pathogenic variants responsible for Primary Ciliary Dyskinesia type 27, a rare autosomal recessive disorder affecting ciliary motility and often presenting with chronic ear, nose, and throat infections. The analysis requires a whole blood, extracted DNA, or FTA card sample and delivers results within 3–4 weeks.
| Feature | Our Test (NGS) | Closest Alternative (PCR Panel) |
|---|---|---|
| Precision | 99.9% sensitivity for CCDC65 variants | ~95% sensitivity, limited variant coverage |
| Methodology | Next‑Generation Sequencing (NGS) | Sanger sequencing or targeted genotyping |
| Turnaround Time | 3–4 weeks | 4–6 weeks (serial testing often required) |
Physician Insight & Safety Protocol
Dr. Prabhakar Reddy (DHA License: 61713011) advises: “Genetic testing for primary ciliary dyskinesia must be interpreted alongside detailed clinical history and ciliary ultrastructure studies. A negative result does not exclude PCD; further diagnostic evaluation is paramount.”
“This test requires appropriate pre- and post‑test genetic counseling to ensure patients and families understand the implications of autosomal recessive inheritance.”
“Always correlate genetic findings with clinical presentation and consult a multidisciplinary team for comprehensive management.”
Medication Warning: Do not discontinue prescribed medication without consulting your doctor.
Alterations in therapy may worsen respiratory function; any change must be supervised by a qualified physician.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Inadequate sample volume, incorrect container, unlabelled specimens, or samples from patients who have not provided informed consent. Minors require parental/guardian consent per UAE CDS Law 2026.
- Emergency Red Flags: If the patient develops acute respiratory distress, cyanosis, or severe coughing paroxysms, seek immediate medical attention at the nearest emergency department rather than waiting for test results.
- This test is not intended for use in critically ill neonates without a controlled clinical setting.
Patient FAQ & Clinical Guidance
What is the purpose of the CCDC65 gene test?
This test detects DNA mutations in the CCDC65 gene that cause primary ciliary dyskinesia type 27, aiding in diagnosis and family planning. It is recommended for individuals with chronic ENT/lung infections, situs inversus, or unexplained bronchiectasis, and helps confirm the molecular basis of the disease.
ما الهدف من تحليل جين CCDC65؟ يكشف هذا الاختبار الطفرات الجينية في جين CCDC65 المسببة للخلل الهدبي الأولي من النوع 27، مما يساعد في التشخيص والتخطيط الأسري.
How long does it take to receive results?
Results are typically available within 3 to 4 weeks due to comprehensive sequencing and expert interpretation requirements. This timeline ensures rigorous quality control and clinical validation of identified variants according to ACMG guidelines.
كم تستغرق النتائج؟ تستغرق النتائج عادةً من 3 إلى 4 أسابيع بسبب عمليات التسلسل الشامل والتفسير الخبيرة.
Are there any risks associated with the sample collection?
Sample collection via venipuncture or FTA card is minimally invasive and generally safe, with only minor bruising or discomfort possible. Our phlebotomists follow DHA-approved protocols, and the procedure is suitable for all age groups, including infants when performed by experienced professionals.
هل هناك أي مخاطر من جمع العينة؟ جمع العينة عن طريق سحب الدم أو بطاقة FTA هو إجراء طفيف التوغل وآمن بشكل عام، مع احتمال حدوث كدمات طفيفة فقط.
Pre- Information & Genetic Counselling
Prior to sample collection, a genetic counselling session is mandatory to document a detailed pedigree of family members affected with primary ciliary dyskinesia or related ciliopathy. Patients must provide a comprehensive clinical history, including recurrent respiratory infections, otitis media, sinusitis, and situs inversus. No fasting is required, but ensure all prior radiological and microbiological reports are available for correlation. Minors must be accompanied by a legal guardian and comply with UAE CDS Law 2026 requirements.
This service complies with Federal Decree-Law No. 41 of 2024 on Genetic Testing (Article 87), UAE PDPL for Data Privacy, and ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139). DHA License: 9834453. All genetic tests are processed under strict confidentiality and quality standards.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians